• 1
    Miners JO & Birkett DJCytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol1998;45 525 538
  • 2
    Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter TMetabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica1998;28 1 13
  • 3
    Bhasker CR, Miners JO, Coulter S, Birkett DJAllelic and functional variability of cytochrome P4502C9. Pharmacogenetics1997;7 51 58
  • 4
    Veronese ME, Doecke CJ, Mackenzie PI,et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J1993;289 533 538
  • 5
    Furuya H, Fernandez Salguero P, Gregory W,et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics1995;5 389 392
  • 6
    Steward DJ, Haining RL, Henne KR,et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics1997;7 361 367
  • 7
    Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther1998;63 519 528
  • 8
    Yamazaki H, Inoue K, Shimada TRoles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica1998;28 103 115
  • 9
    Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada TRelationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics1997;7 103 113
  • 10
    Kumar GN, Dubberke E, Rodrigues AD, Roberts E, Dennisen JFIdentification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos1997;25 110 115
  • 11
    Goldstein JA & De Morais SMBiochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics1994;4 285 299
  • 12
    Kalow WInterethnic variation of drug metabolism. Trends Pharmacol Sci1991;12 102 107
  • 13
    Idle JR, Sloan TP, Smith RL, Wakile LAApplication of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings]. Br J Pharmacol1979;66 430P 431P
  • 14
    Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJValidation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther1990;47 403 411
  • 15
    Dickinson RG, Hooper WD, Patterson M, Eadie MJ, Maguire BExtent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit1985;7 283 289
  • 16
    Brockmöller J, Rost KL, Gross D, Schenkel A, Roots IPhenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G[RIGHTWARDS ARROW]A-splice site mutation. Pharmacogenetics1995;5 80 88
  • 17
    London SJ, Daly AK, Leathart JB, Navidi WC, Idle JRLung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics1996;6 527 533
  • 18
    Ackermann E, Cascorbi I, Sachse C, Brockmöller J, Roots IA novel CYP2C9 intron 2 T/C transition and linkage of mutations Cys144 and Leu359. 12th International Symposium on Microsomes and Drug Oxidations 1998 Montpellier, France.
  • 19
    Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KRImpaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics1994;4 39 42
  • 20
    Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AEAllelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys1996;333 447 458
  • 21
    Spielberg S, McCrea J, Cribb A,et al.A mutation in CYP2C9 is responsible for decreased metabolism of losartan. 97th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics 1996 Florida, USA.
  • 22
    Fritz S, Lindner W, Roots I, Frey BM, Kupfer AStereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther1987;241 615 622
  • 23
    Ieiri I, Goto W, Hirata K, et al. Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic gingival hyperplasia: in vivo and in vitro study. Eur J Clin Pharmacol1995;49 51 56